Description:
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (which the study team will see in the
tumor that is taken out at the time of surgery)
2. Improvement in long term survival rates
Title
- Brief Title: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
- Official Title: Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (Anti-IL-8) for NSCLC or HCC
Clinical Trial IDs
- ORG STUDY ID:
GCO 19-1754
- NCT ID:
NCT04123379
Conditions
- Non-small Cell Lung Cancer
- Hepatocellular Carcinoma
Interventions
Drug | Synonyms | Arms |
---|
Nivolumab | | Cohort A |
BMS-813160 | CCR2/5-inhibitor | Cohort A |
BMS-986253 | anti-IL-8 | Cohort B |
Purpose
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (which the study team will see in the
tumor that is taken out at the time of surgery)
2. Improvement in long term survival rates
Detailed Description
Objectives:
Cohorts A,B (NSCLC):
Primary Objective: Major Pathologic Response (MPR) Secondary Objectives: Time to surgery,
tolerability and safety, radiographic response
Cohorts C,D,E (HCC):
Primary Objective: Significant tumor necrosis (STN) Secondary Objectives: Time to surgery,
tolerability and safety, radiographic response
Diagnosis and Main Inclusion Criteria:
Patients must have disease deemed resectable before enrollment.
Study Product:
Nivolumab 480mg (q4w, dosed twice before surgery and three times following recovery from
surgery) BMS-813160 (CCR2/5-inhibitor) 300mg oral twice a day for 28 days BMS-986253
(anti-IL-8) 2400mg once
Trial Arms
Name | Type | Description | Interventions |
---|
Cohort A | Experimental | NSCLC: Nivolumab + BMS-813160 | |
Cohort B | Experimental | NSCLC: Nivolumab + BMS-986253 | |
Cohort C | Experimental | HCC: Nivolumab | |
Cohort D | Experimental | HCC: Nivolumab + BMS-813160 | |
Cohort E | Experimental | HCC: Nivolumab + BMS-986253 | |
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of NSCLC or HCC
- Willing to provide blood samples
- Willing to undergo leukapheresis at Mount Sinai Hospital or New York Blood Bank
- Willing to have excisional or core needle biopsies
- At least 18 years of age
- ECOG 0-1
- Surgical candidate for resection of their tumor
- Agree to use adequate contraception
- Adequate organ and marrow function
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 months for a different
primary tumor or patients who have received locoregional therapy for the target lesion
- Patients receiving any other investigational agents
- Patients with metastatic disease for whom the intent of surgery would not be curative
- Uncontrolled intercurrent illness
- Pregnant or nursing
- Has a diagnosis of primary immunodeficiency or is receiving systemic steroid therapy
or any other form of immunosuppressive therapy within 7 days
- Has active autoimmune disease that has required systemic treatment in the past year
- Has a known additional malignancy that is progressing and/or requires active treatment
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the patient's
participation for the full duration of the trial, or is not the in the best interest
of the patient to participate
- HIV positive with detectable viral load or anyone not on stable anti-viral regimen
- Has known active Hepatitis B
- History of allogeneic hematopoietic cell transplantation or solid organ
transplantation
- Documented allergic or hypersensitivity response to any protein therapeutics
- Patients may not have prolonged QRS or QTc
Maximum Eligible Age: | 99 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Major Pathologic Response (MPR) |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | MPR is defined as <10% viable tumor within resection, at time of surgery. |
Secondary Outcome Measures
Measure: | Time to Surgery |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | Measured as the time in days that elapses between the first dose of neoadjuvant therapy and surgical resection. |
Measure: | Percent of individuals who experience adverse events |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | Safety and Tolerability defined by the percent of individuals who experience adverse events at any point during the neoadjuvant period, or within 30 days following the final dose of nivolumab received. |
Measure: | Percent of individuals who experience radiographic response |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | As per RECIST v1.1 as determined by pre-surgical imaging, following receipt of the neoadjuvant therapy. For NSCLC this will be based on CT imaging, while for HCC this imaging will be based on MRI radiographic post-contract subtraction. |
Measure: | Progression-free survival (PFS) |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | Defined as the time, in days, between treatment initiation and when the patient is found to have recurrent and/or metastatic disease on imaging, or death for any reason. |
Measure: | Overall Survival (OS) |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | Defined as the time, in days, between treatment initiation and when the patient dies from any cause regardless of etiology. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Icahn School of Medicine at Mount Sinai |
Trial Keywords
- Nivolumab
- CCR2/5-inhibitor
- anti-IL-8
Last Updated
September 30, 2020